相似文献
1
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
Cancer Discov. 2021 Feb;11(2):233-236. doi: 10.1158/2159-8290.CD-20-1817. Epub 2020 Dec 19.
2
Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.
Vaccine. 2021 Jan 8;39(2):255-262. doi: 10.1016/j.vaccine.2020.12.010. Epub 2020 Dec 13.
3
[The vaccines are here: Are we ready?].
Biomedica. 2021 Mar 19;41(1):5-7. doi: 10.7705/biomedica.6072.
4
Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.
Cancer Control. 2022 Jan-Dec;29:10732748211070720. doi: 10.1177/10732748211070720.
5
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.
Semin Hematol. 2022 Oct;59(4):192-197. doi: 10.1053/j.seminhematol.2022.11.001. Epub 2022 Nov 19.
6
Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
Eur J Haematol. 2022 Feb;108(2):91-98. doi: 10.1111/ejh.13722. Epub 2021 Dec 5.
7
A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
Chest. 2021 Mar;159(3):1292-1293. doi: 10.1016/j.chest.2020.08.2042. Epub 2021 Jan 14.
8
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.
Cancer Cell. 2022 Feb 14;40(2):114-116. doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29.
9
COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments.
Acta Haematol. 2022;145(3):244-256. doi: 10.1159/000522436. Epub 2022 Feb 8.
10
Rationing of Civilian Coronavirus Disease 2019 Vaccines While Supplies Are Limited.
J Infect Dis. 2020 Nov 9;222(11):1776-1779. doi: 10.1093/infdis/jiaa569.
引用本文的文献
1
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy.
Cancers (Basel). 2025 Jun 2;17(11):1865. doi: 10.3390/cancers17111865.
2
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.
BMJ Oncol. 2023 Dec 14;2(1):e000054. doi: 10.1136/bmjonc-2023-000054. eCollection 2023.
3
Is COVID-19 Vaccination Beneficial for Tumor Patients: A Cross-Sectional Investigation in China.
Immun Inflamm Dis. 2024 Nov;12(11):e70069. doi: 10.1002/iid3.70069.
4
Prognostic model for gastric cancer patients with COVID-19 and network pharmacology study on treatment by lentinan.
Sci Rep. 2024 Oct 20;14(1):24645. doi: 10.1038/s41598-024-76783-2.
5
Low booster uptake in cancer patients despite health benefits.
iScience. 2024 Jul 26;27(9):110596. doi: 10.1016/j.isci.2024.110596. eCollection 2024 Sep 20.
6
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.
Front Immunol. 2024 Aug 27;15:1447555. doi: 10.3389/fimmu.2024.1447555. eCollection 2024.
7
Association between prostate cancer and susceptibility, hospitalization, and severity of COVID-19: Based on a Mendelian randomization study.
Medicine (Baltimore). 2024 Sep 6;103(36):e39430. doi: 10.1097/MD.0000000000039430.
8
Increased Risk of Breakthrough SARS-CoV-2 Infections in Patients with Colorectal Cancer: A Population-Based Propensity-Matched Analysis.
J Clin Med. 2024 Apr 24;13(9):2495. doi: 10.3390/jcm13092495.
9
Survival and safety analysis of COVID-19 vaccine in Chinese patients with non-small cell lung cancer.
Cancer Med. 2024 Apr;13(8):e7032. doi: 10.1002/cam4.7032.
10
Age, Gender, and Liver Enzyme Impact Hospital Stay in COVID-19 Minority Patient with Cancer in the USA: Does Race Matters in the Pandemic?
Ann Clin Med Case Rep. 2024;13. Epub 2024 Mar 21.
本文引用的文献
1
COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
Blood Cancer Discov. 2020 Jul 30;1(3):234-243. doi: 10.1158/2643-3230.BCD-20-0102. eCollection 2020 Nov.
2
Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.
Front Oncol. 2020 Nov 20;10:595804. doi: 10.3389/fonc.2020.595804. eCollection 2020.
3
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859. doi: 10.15585/mmwr.mm6949e1.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection.
JAMA Oncol. 2021 Feb 1;7(2):220-227. doi: 10.1001/jamaoncol.2020.6178.
6
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
7
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities.
Blood Rev. 2021 May;47:100775. doi: 10.1016/j.blre.2020.100775. Epub 2020 Nov 9.
8
COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
Ann Hematol. 2021 Feb;100(2):383-393. doi: 10.1007/s00277-020-04328-4. Epub 2020 Nov 7.
9
Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380. doi: 10.1093/jnci/djaa168.
10
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.
Cancer. 2021 Jan 15;127(2):266-274. doi: 10.1002/cncr.33243. Epub 2020 Oct 28.
Zotero 插件